Plain-English translation of NCT06313398 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This research uses a safe, harmless labeling technique called biotin labeling to track how long your red blood cells survive in your body. Researchers will label some of your red blood cells with biotin (a common B vitamin) and then measure how long they stay in your bloodstream. This helps doctors understand how well treatments are working for blood disorders like sickle cell disease and thalassemia.
People with sickle cell disease and similar blood disorders have red blood cells that don't live as long as they should, which contributes to their symptoms. This study will help doctors understand which treatments actually improve red blood cell survival and by how much, which could help them better predict which patients will benefit from different therapies.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn, and your red blood cells will be labeled with biotin in the laboratory and then given back to you through an infusion. Over the following weeks and months, you will return for blood draws so researchers can track how long the labeled cells stay in your bloodstream. The study follows you before and after you start a new treatment or transplant, allowing doctors to see how the therapy affects your red blood cell survival.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States